1. Teva Pharmaceutical Industries is reportedly planning to lay off up to 10,000 employees at its R&D center in Israel and sell a logistics center to chip away at its $35 billion debt. The drugmaker also announced the resignation of former chairman and interim CEO Yitzhak Peterburg, effective Tuesday. (Endpoints News)   

2. The FDA plans to study the ability of doctors and consumers to decipher deceptive pharma ads that could lead to unnecessary prescribing. (Stat)

3. The combination of AbbVie and Roche’s Venclexta along with Roche and Biogen’s Rituxan was more effective in treating second-line cases of chronic lymphocytic leukemia than standard of care, according to Phase-III trial data released at ASH. (Endpoints News)

4. Sanofi said that it plans to submit 19 pipeline drugs for approval in the next 18 months and that it remains “on track” to sell its European generics business, deemed to be worth $2.4 billion. The drugmaker is under scrutiny for rolling out its dengue vaccine Dengvaxia in the Philippines despite safety concerns. (Reuters)

5. The FDA proposed a fast-track program for certain medical devices that would reduce the amount of safety data required to receive approval. Eligible devices would no longer be required to present a pre-existing equivalent, or predicate. (Reuters)